Medicenna Announces Results of Annual and Special Meeting of Shareholders
September 28, 2023 17:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ, TSX: MDNA), a clinical-stage immuno-oncology company focused on the...
Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy
September 28, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the...
Medicenna to Participate at The H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the...
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
August 28, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella’s appointment...
Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management
August 14, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
Company to grow business development, financing and clinical leadership in Boston by accessing top-biotech talent.Brent Meadows, MBA, joins as Chief Business Officer (CBO), bringing over 25 years of...
Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study
August 09, 2023 07:30 ET
|
Medicenna Therapeutics Corp.
- Durable anti-cancer activity was observed during monotherapy dose escalation without dose-limiting toxicities - Late-stage pancreatic cancer patient achieved 80% tumor shrinkage with complete...
Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee
August 08, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today...
Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023
August 04, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today...
Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology
August 01, 2023 09:30 ET
|
Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp. has been granted U.S. Patent No. 11,680,090 titled “Interleukin-2 Fusion Proteins and Uses Thereof.”The patent covers a method for enhancing immune cell survival and...
Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights
July 28, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
Safety Review Committee clears MDNA11 Cohort 6 dose of 120µg/Kg, Q2W, in the Phase 1 portion of the ABILITY Study as there were no protocol defined dose-limiting toxicitiesMDNA11 clinical update...